Tel Aviv, Israel and Oslo, Norway – May 22, 2026
BioLineRx Ltd. and Hemispherian AS announced new preclinical and clinical development data for GLIX1, a first-in-class oral small molecule targeting the DNA damage response pathway, at the upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting. The data strengthen the scientific rationale for GLIX1 as a potential breakthrough therapy for glioblastoma (GBM) and multiple solid tumors, highlighting the growing importance of novel DNA repair-targeting approaches in oncology. The companies believe the therapy’s unique mechanism of action could address major unmet needs in aggressive cancers with limited treatment options.
GLIX1 Targets DNA Damage Response Through TET2 Activation
The ASCO presentations focus on GLIX1’s ability to restore activity of the TET2 enzyme, a critical regulator of DNA demethylation that is often suppressed in cancer cells. Researchers explained that impaired TET2 activity contributes to abnormal DNA hypermethylation and tumor progression. By reactivating TET2, GLIX1 induces excessive DNA repair activity that ultimately overwhelms cancer cells and triggers lethal DNA strand breaks.
According to the companies, preclinical studies demonstrated strong antitumor activity across multiple cancer cell lines and glioblastoma animal models. GLIX1 showed high potency in vitro and successfully penetrated the brain following oral administration, achieving brain exposure levels reaching 68% to 85% of plasma concentrations in mice. Researchers also reported favorable safety findings in animal studies, where the therapy remained well tolerated even at very high dose levels in rats and dogs.
The findings are especially significant for glioblastoma, one of the most aggressive and treatment-resistant brain cancers. Current standard treatment for GBM has changed little over the past two decades, and survival outcomes remain poor for many patients. Scientists believe GLIX1’s tumor-selective DNA damage mechanism may provide a new therapeutic strategy capable of overcoming resistance seen with existing treatments.
Advertisement
Combination Strategy With PARP Inhibitors Shows Strong Potential
A second ASCO abstract highlighted GLIX1’s synergistic potential when combined with PARP inhibitors, a widely used class of targeted oncology drugs that interfere with DNA repair mechanisms. PARP inhibitors are effective in certain genetically vulnerable cancers but often show limited activity in tumors with intact homologous recombination repair pathways.
Researchers found that GLIX1 significantly increased tumor-selective DNA damage, creating a strong mechanistic basis for combination therapy with PARP inhibition. In preclinical laboratory studies, combining GLIX1 with multiple PARP inhibitors produced robust cytotoxic effects across a wide range of cancer cell types, including tumors traditionally less responsive to PARP-targeted therapies.
Importantly, the synergy appeared consistent across different PARP inhibitors, suggesting the approach could have broad applicability rather than being dependent on a single drug combination. The companies stated that these findings support further investigation of GLIX1-based combination strategies in both glioblastoma and other solid tumors.
Phase 1/2a Clinical Trial Advances in Glioblastoma
BioLineRx confirmed that a first-in-human Phase 1/2a clinical trial evaluating GLIX1 in recurrent and progressive glioblastoma patients was initiated earlier this year. The open-label, multicenter study is designed to assess safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of the therapy as a monotherapy treatment.
The dose-escalation portion of the study is expected to enroll up to 30 patients with recurrent GBM and other high-grade gliomas. Researchers aim to establish the maximum tolerated dose and identify an optimal dose for future development. Additional expansion cohorts planned for Phase 2a are expected to evaluate GLIX1 in newly diagnosed GBM and selected solid tumors, including combination approaches with PARP inhibitors and standard-of-care therapies.
Industry experts believe the development of GLIX1 reflects the increasing focus on precision oncology, particularly therapies targeting the cellular DNA repair system. With glioblastoma continuing to represent one of the largest unmet needs in cancer treatment, successful development of novel therapies like GLIX1 could significantly influence future neuro-oncology treatment strategies worldwide.
Source: BioLineRx, Hemispherian AS press release
